Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
18 studies found for:    "Hyperlipoproteinemia type 5"
Show Display Options
Rank Status Study
1 Terminated MK0859 Dose-Ranging Study (0859-003)
Conditions: Hypercholesterolemia;   Mixed Hyperlipemia
Intervention: Drug: MK0859
2 Completed
Has Results
Effect of Rosuvastatin on Triglyceride Levels in Mexican Hypertriglyceridemic Patients
Conditions: Hypertriglyceridemia;   Hyperlipoproteinemia Type IV;   Hyperlipoproteinemia Type V;   Hyperlipoproteinemia Type IIb;   Hyperlipidemia
Intervention: Drug: rosuvastatin
3 Completed A Study to Evaluate an Investigational Drug in Patients With Mixed Hyperlipidemia (0653A-071)(COMPLETED)
Conditions: Hyperlipidemia;   Hypercholesterolemia;   Hypertriglyceridemia
Intervention: Drug: ezetimibe (+) simvastatin
4 Completed Lipid Efficacy Study
Conditions: Primary Hypercholesterolemia;   Mixed Hyperlipidemia
Interventions: Drug: niacin (+) laropiprant (+) simvastatin;   Drug: Comparator:  niacin (+) laropiprant;   Drug: Comparator: simvastatin
5 Unknown  Comparison of High-Dose Rosuvastatin Versus Low Statin Dose Plus Fenofibrate Versus Low Statin Dose Plus Niacin in the Treatment of Mixed Hyperlipidemia
Condition: Dyslipidemia
Interventions: Drug: High-dose rosuvastatin;   Drug: Statin plus fenofibrate;   Drug: Statin plus niacin ER/laropiprant
6 Recruiting Comparison of the Efficacy and Safety of AtorVastatin mOnotherapy vs. Combination Atorvastatin/Fenofibric Acid
Condition: Mixed Hyperlipidemia
Interventions: Drug: Atorvastatin 10mg, fenofibric acid 135mg;   Drug: atorvastatin 20mg
7 Completed Phase 2 Dose-Ranging Efficacy and Safety Trial of SCH 900271 in Subjects With Primary Hypercholesterolemia or Mixed Hyperlipidemia (P05675)
Conditions: Primary Hypercholesterolemia;   Mixed Hyperlipidemia
Interventions: Drug: SCH 900271;   Drug: Placebo
8 Completed
Has Results
A Study to Evaluate the Effects of Laropiprant on the Antiplatelet Effects of Clopidogrel and Aspirin in Combination (MK-0524A-114)(COMPLETED)
Conditions: Primary Hypercholesterolemia;   Mixed Hyperlipidemia
Interventions: Drug: niacin (+) laropiprant;   Drug: Comparator: aspirin;   Drug: Comparator: clopidogrel;   Drug: Comparator: laropiprant;   Drug: Comparator: placebo
9 Withdrawn Efficacy Study of Daily Pro-Omega LDL for Low-Density Lipoprotein Cholesterol and Triglyceride Reduction
Condition: Mixed Hyperlipoproteinemia
Interventions: Dietary Supplement: Pro-Omega LDL;   Other: Placebo
10 Recruiting Efficacy and Safety of Fenofibrate Added on to Atorvastatin Compared With Atorvastatin in Mixed Hypercholesterolemic Patient(CKD-337)
Condition: Mixed Hyperlipidemia
Interventions: Drug: Atorvastatin 20mg;   Drug: Fenofibrate 160mg;   Other: Placebo (Fenofibrate 160 mg)
11 Terminated Carotid B-mode Ultrasound Study to Compare Anti-Atherosclerotic Effect of Torcetrapib/Atorvastatin to Atorvastatin.
Condition: Mixed Hyperlipidemia
Interventions: Drug: torcetrapib/atorvastatin;   Drug: atorvastatin
12 Completed Two Investigational Drugs in Patients With Mixed Hyperlipidemia (0653-036)
Conditions: Hypercholesterolemia;   Hypertriglyceridemia
Interventions: Drug: MK0653, ezetimibe;   Drug: Comparator: fenofibrate monotherapy
13 Completed Lipid Efficacy and Safety in Patients With Mixed Hyperlipidemia (MK-0524B-024)
Condition: Mixed Hyperlipidemia
Interventions: Drug: Comparator: MK0524B;   Drug: Comparator: Atorvastatin
14 Completed Lipid Efficacy/Tolerability Study (0524A-020)
Conditions: Primary Hypercholesterolaemia;   Mixed Hyperlipidaemia
Interventions: Drug: niacin (+) laropiprant;   Drug: ER-niacin
15 Recruiting A Pilot Study to Evaluate the Lipid Effects of TRIA-662
Conditions: Hypertriglyceridemia;   Mixed Hyperlipidemia
Interventions: Drug: TRIA-662;   Drug: Placebo
16 Completed Study of Ezetimibe and Fenofibrate in Patients With Mixed Hyperlipidemia (0653-036)(COMPLETED)
Conditions: Hypercholesterolemia;   Hypertriglyceridemia
Interventions: Drug: MK0653, ezetimibe;   Drug: Comparator: fenofibrate monotherapy
17 Completed Efficacy Study of Extended-Release Niacin/Lovastatin Versus Usual Care
Conditions: Hyperlipidemia;   Mixed Hyperlipidemia;   Dyslipidemia
Intervention: Drug: Niacin Extended Release/Lovastatin
18 Withdrawn Efficacy of Ezetimibe/Simvastatin 10/20 mg and MK0524A (1-2 g/Day) in Mixed Hyperlipidemia and Two or More Risk Factors
Conditions: Cardiovascular Diseases;   Hyperlipidemia
Interventions: Drug: ezetimibe/simvastatin 10/20 mg + placebo;   Drug: ezetimibe/simvastatin 10/20 mg + MK0524A

Indicates status has not been verified in more than two years